南新制藥(688189.SH)擬投資3.26億元超募資金建設帕拉米韋生產基地三期工程項目
格隆匯11月24日丨南新制藥(688189.SH)公佈,隨着公司研發工作的推進,為滿足產品中試、技術改進及後續獲批產品的生產需要,結合公司戰略發展目標,擬在廣州南鑫藥業有限公司廠區內投資約人民幣4.31億元建設帕拉米韋生產基地三期工程項目,其中擬使用超募資金3.26億元,剩餘部分由公司以自有資金或自籌資金投入。
項目擬建於廣州南鑫藥業有限公司廠區內,廠區總佔地面積為41,116.00m2,容積率1.512,總建築面積為62,134.30m2,建築密度45.30%,已建成工程建築物總佔地面積9,270.80m2,總建築面積28,849.30m2,本項目計劃工程建築物總佔地面積9,314.00m2,總建築面積33,285.00m2。
項目一次規劃,分期實施,該項目建設週期為2020年12月-2025年11月,全部建設內容擬在1-5年內陸續建成投入使用。
該項目計劃投資總額為4.31億元,其中建築工程費2.12億元,設備購置安裝費1.90億元,預備費2919.47萬元。資金來源主要為公司超募資金和自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.